Sagimet Biosciences
SGMT
Sagimet Biosciences (SGMT) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $29.00 | Oct 5, 2026 |
| Guggenheim | Maintained | Buy | $26.00 from $25.00 | Oct 2, 2026 |
| Oppenheimer | Maintained | Outperform | $38.00 from $33.00 | Oct 1, 2026 |
| Citizens | Maintained | Market Outperform | $27.00 from $29.00 | Oct 1, 2026 |
| Goldman Sachs | Maintained | Sell | $7.00 | Sep 24, 2026 |
| Barclays | Upgraded | Equal-Weight → Overweight | $18.00 from $8.00 | Sep 9, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $10.71 | Sep 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $29.00 | Aug 25, 2026 |
| Citizens | Maintained | Market Outperform | $29.00 from $12.00 | Aug 14, 2026 |
| Canaccord Genuity | Maintained | Buy | $56.00 from $49.00 | Aug 12, 2026 |
| Citizens | Maintained | Market Outperform | $12.00 from $35.00 | May 19, 2026 |
| Canaccord Genuity | Maintained | Buy | $49.00 from $28.00 | May 4, 2026 |
| Guggenheim | Maintained | Buy | $25.00 from $27.00 | Apr 29, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $29.00 | Mar 11, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $29.00 | Feb 3, 2026 |
| Guggenheim | Initiated Coverage | Buy | $27.00 | Feb 3, 2026 |
| Barclays | Initiated Coverage | Equal-Weight | $8.00 | Jan 28, 2026 |
| Citizens | Maintained | Market Outperform | $35.00 from $33.00 | Nov 14, 2025 |
| Clear Street | Initiated Coverage | Buy | $29.00 | Oct 22, 2025 |
| Canaccord Genuity | Maintained | Buy | $28.00 | Oct 2, 2025 |
Frequently asked questions
What is the latest analyst rating on SGMT?
On Oct 5, 2026, HC Wainwright & Co. maintained Sagimet Biosciences at Buy with a price target of $29.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.